Persistence of Biological Treatment and Inhibitors of Jak Kinases in Habitual Clinical Practice in Patients With Rheumatoid Arthritis. Influence of the Comorbidities.
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients aged ≥18 years.
• With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria.
• Who have received at least one of the doses of the study drugs.
• In follow-up in the consultations of the UGC of Rheumatology of the HUVM.
• With at least two complete evaluations (baseline and final) of clinical variables.
Locations
Other Locations
Spain
Hospital Universitario Virgen macarena
RECRUITING
Seville
Contact Information
Primary
Blanca Estela Hernández Cruz
blancahcruz@gmail.com
955008000
Backup
Carlos García Pérez
administracion.eecc.hvm.sspa@juntadeandalucia.es
955 04 31 27
Time Frame
Start Date: 2021-04-01
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 540
Treatments
Cases 1
Patients treated with JAK-type kinase inhibitors.
Cases 2
Patients treated with monoclonal antibodies against TNF.
Cases 3
Patients treated with soluble receptor against TNF.
Cases 4
Patients treated with FAME group biosimilars.
Cases 5
Patients treated with rituximab.
Cases 6
Patients treated with abatacept.
Cases 7
Patients treated with drugs that block the IL6.
Related Therapeutic Areas
Sponsors
Leads: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla